The FDA Is Narrowing HRT's Black Box Warning: What Changed and What Didn't

For more than two decades, a black box warning - the most serious type of warning the FDA can place on a medication - sat on every hormone replacement therapy product in the United States. For millions of women suffering through perimenopause and menopause, that warning was enough to keep them from seeking treatment that could have transformed their quality of life.

The short answer: the FDA is updating menopausal hormone therapy labels product by product. Updated labels drop the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning, but updated systemic estrogen-alone labels keep the endometrial cancer warning. Contraindications did not change, and products without an FDA-approved labeling update may still carry the older warning.

What the FDA changed

In November 2025, the FDA requested these labeling changes from manufacturers. In February 2026, it approved the first six updated labels. The change does not apply to every menopausal hormone product at once and does not make hormone therapy appropriate for everyone.

The FDA requested removal of three risk statements from the boxed warning: cardiovascular disease, breast cancer and probable dementia. Those statements are gone only from labels the FDA has actually updated; other products may still carry the older boxed warning.

One boxed warning was deliberately retained on updated systemic estrogen-alone labels. The endometrial cancer warning remains for use in a woman with a uterus without adequate protection of the uterine lining. Low-dose vaginal estrogen generally does not require an added progestogen. Check the current label for the specific product.

The rollout is still in progress. As of September 10, 2026, the FDA lists six products with updated prescribing information: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.

One thing the FDA did not touch is the contraindications section. A history of blood clots, stroke or heart attack, active liver disease, and current or past breast cancer are all still listed as reasons not to use systemic estrogen. The warning label changed; who the drug is licensed for did not.

What happened and why it matters

The black box warnings were added to HRT products in 2002 and 2003, following the publication of the Women's Health Initiative (WHI) study. That study, which examined hormone therapy in postmenopausal women, initially reported increased risks of breast cancer, heart disease, stroke, and blood clots. The findings sent shockwaves through the medical community and terrified women everywhere.

Almost overnight, millions of women stopped taking HRT. Doctors became reluctant to prescribe it. Medical schools reduced menopause training. And an entire generation of women was left to suffer through debilitating symptoms with little support.

But here's what most people never heard: the WHI study had serious limitations, and its findings were widely misinterpreted. The women in the study were primarily in their 60s and 70s - well past menopause - and many had pre-existing cardiovascular risk factors. The study was never designed to evaluate HRT in the women who actually need it most: those in their 40s and 50s experiencing active perimenopause and menopause symptoms.

What 20 years of follow-up research actually showed

In the two decades since the WHI, extensive reanalysis and follow-up studies have painted a very different picture:

• For women who start HRT within 10 years of menopause onset (the "timing hypothesis"), the benefits significantly outweigh the risks for most women.
• Estrogen-only HRT (for women without a uterus) was actually associated with a decreased risk of breast cancer in long-term WHI follow-up.
• Transdermal estrogen (patches, gels, sprays) does not carry the same blood clot risk as oral estrogen.
• Micronized progesterone (like Prometrium) appears to be safer than the synthetic progestin (medroxyprogesterone) used in the original WHI study.
• Cardiovascular risk appears more favorable when HRT is started in younger, recently menopausal women than when it is started later - the "window of opportunity." HRT is not approved to prevent heart disease.

The medical consensus has shifted dramatically. The Menopause Society (formerly NAMS), the Endocrine Society, and multiple international medical organizations now support the use of HRT for symptomatic women under 60 or within 10 years of menopause onset.

Why the FDA acted now

The FDA's decision to narrow the black box warnings follows a long-running argument among menopause specialists that the warnings, based largely on the 2002 WHI results, overstated the risks for younger, recently menopausal women and discouraged some from seeking effective treatment.

In announcing the change, the Department of Health and Human Services described the warnings as "misleading" and said they did not reflect the current state of the scientific evidence.

This doesn't mean HRT is risk-free - no medication is. But for healthy symptomatic women under 60 or within 10 years of menopause who have no contraindications, major menopause societies consider the benefits of treatment generally greater than the risks. The black box warning was a blunt instrument that failed to distinguish between different types of HRT, different delivery methods, different patient populations, and different timing of initiation.

What this means for you

If you've been hesitant about HRT because of safety concerns, here's what you should know:

The FDA's action is not about making HRT seem "safe for everyone." It's about narrowing a warning that painted all HRT with the same broad brush and scared some women away from individually appropriate treatment decisions.

HRT is still a personal medical decision that should be made with a qualified provider who understands your individual health history, risk factors, and symptoms. The right approach varies from person to person.

The type of HRT matters. Transdermal estrogen (patches, gels, sprays) is associated with a lower risk of blood clots than oral estrogen in observational studies. Micronized progesterone appears to have a more favorable risk profile than some synthetic progestins. Bioidentical hormones are structurally identical to what your body produces. Your provider can help you navigate these choices.

Timing matters. Starting HRT within 10 years of menopause onset or before age 60 is associated with the most favorable benefit-to-risk ratio. If you're in perimenopause or early menopause, you're in the optimal window.

You don't have to suffer. Hot flashes, night sweats, brain fog, mood changes, sleep disruption, weight gain, joint pain - these symptoms are not just "part of aging." They're the result of hormonal changes, and they're treatable.

What to do next

If you've been struggling with perimenopause or menopause symptoms and have been afraid to explore HRT, this is your sign to take the next step. Find a provider who specializes in hormone health - someone who stays current on the research and can have an honest, nuanced conversation about your individual risks and benefits.

The conversation about HRT has changed. The science has evolved. And you deserve care that reflects what we actually know in 2026 - not the fear that was generated by a misinterpreted study from 2002.

You deserve to feel like yourself again. The FDA's action supports a more current, product-specific conversation about benefits and risks.